• Medium spiny neurons MSNs in

  2024-04-28

  

  Medium spiny neurons (MSNs) in the striatum start from a deeply hyperpolarized resting membrane potential, slowly depolarize and show a delayed start of firing during a current injection (Kawaguchi, 1993, Nisenbaum and Wilson, 1995, Planert et al., 2013). The firing pattern during the current inject

• br Introduction In myasthenia gravis MG autoantibodies again

  2024-04-28

  

  Introduction In myasthenia gravis (MG), autoantibodies against the native AChR conformation cause loss of AChR at the neuromuscular junction and fatigable muscle weakness (Newsom-Davis et al., 1993). The AChR is a pentameric transmembrane protein, with two splice forms of the α-subunit, P3A− and

• The first suggestions that the cleaved

  2024-04-28

  

  The first suggestions that the cleaved intracellular domain of APP, AICD, might transit to the nucleus and hence selectively regulate gene transcription arose from analogies with the Notch receptor signalling system where similar intra-membrane proteolysis occurs [84], [85] and it was later confirme

• The adult muscle type acetylcholine receptor AChR

  2024-04-28

  

  The adult muscle-type IOX-2 receptor receptor (AChR), the exemplar pLGIC, is a heteropentamer comprising two α subunits, and one each of the β, δ, and ɛ subunits (Sine, 2012). These five subunits come together in a counterclockwise α-ɛ-α-δ-β arrangement (Figure 1A). Binding of acetylcholine to the A

• br The role of cytochrome b with

  2024-04-28

  

  The role of cytochrome b5 with cytochrome P450 17α-hydroxylase/17,20-lyase Conclusion Acknowledgments LLM and RJR wish to thank the Australian Research Council and the National Health and Medical Research Council of Australia for funding. The problem One area of modern medicine that con

• Introduction Cancer which is responsible for

  2024-04-28

  

  Introduction Cancer, which is responsible for a million deaths each year, is universally feared, and approximately 50% of newly diagnosed cases can be cured [1]. The existing cancer treatments, including surgery, chemotherapy, radiotherapy or a combination of them, are quickly losing efficacy. The

• br Acknowledgments This work was supported by the

  2024-04-27

  

  Acknowledgments This work was supported by the Swiss National Science Foundation. 15-Lipoxygenase 1 (15-LOX-1) is a nonheme, iron-containing enzyme predominantly expressed in reticulocytes, eosinophils, macrophages, mast cells, and bronchial epithelial cells . 15-LOX-1 is a key enzyme involved

• br Material and methods br Results br Discussion

  2024-04-27

  

  Material and methods Results Discussion This study explores the hypothesis that ASK1, via transcriptional upregulation by E2F1, molecularly defines AT that supports a dys-metabolic obese phenotype in humans. We demonstrate associations between increased visceral-AT ASK1 expression and multi

• br Acknowledgment This study was supported by Japan Society

  2024-04-27

  

  Acknowledgment This study was supported by Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (KAKENHI) [grant number 15K15031]. Introduction Glioma is the leading malignancy of astrocyte origin in the brain. The most aggressive, invasive, and destructive glioma

• br Antibiotic drug discovery approaches Traditionally novel

  2024-04-27

  

  Antibiotic drug discovery approaches Traditionally, novel Boc-Phe-Osu were largely discovered by phenotypic screening approaches of various sources of compounds, such as natural products isolated from extracts of soil microbes and semi-synthetic or fully synthetic compound libraries derived from

• br Conclus o br Conflitos de interesses

  2024-04-27

  

  Conclusão Conflitos de interesses Alzheimer Disease: Common and Complex Alzheimer’s disease (AD) is a genetically complex, multifactorial disease that leads to neurodegenerative dementia. There is no cure for AD yet, and due to a high prevalence and continuously increasing incidence it pose

• br Development of lorlatinib from crizotinib to a

  2024-04-27

  

  Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes

• Polycyclic aromatic hydrocarbons PAHs are abundant environme

  2024-04-27

  

  Polycyclic aromatic hydrocarbons (PAHs) are abundant environmental contaminants that are produced by the incomplete combustion of organic matter, combustion engines, residential heating, Piroxicam burning, and industrial activities (Gelboin, 1980; Phillips, 1999, Phillips, 2002). Some PAHs have bee

• br Effective therapeutic window of AR actions on ROP Retinal

  2024-04-26

  

  Effective therapeutic window of AR actions on ROP Retinal vasculature undergoes critical developmental changes postnatally: from P7 onward the superficial PF 04418948 start sprouting vertically in retina to form first the deep then the intermediated vascular plexus in the retina of C57BL/6 mice

• Structure activity relationships biochemical metabolic and

  2024-04-26

  

  Structure–activity relationships [23], [24], [25], [26], biochemical [24], [25], [26], [27], [28], [29], [30], [31], metabolic [19], [27], [28], [29], [30], [31], and molecular [32] investigations have demonstrated that the substrate specificity, as well as other characteristics of T. gondii adenosi

14896 records 136/994 page Previous Next First page 上5页 136137138139140 下5页 Last page